Mizuho Securities USA LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 46.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,946 shares of the medical research company's stock after buying an additional 16,103 shares during the quarter. Mizuho Securities USA LLC's holdings in Amgen were worth $13,279,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in the stock. Swedbank AB raised its stake in Amgen by 1.1% during the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company's stock valued at $173,639,000 after acquiring an additional 5,751 shares in the last quarter. Quest Partners LLC raised its stake in shares of Amgen by 1,568.7% during the third quarter. Quest Partners LLC now owns 1,919 shares of the medical research company's stock valued at $618,000 after purchasing an additional 1,804 shares in the last quarter. Citizens Financial Group Inc. RI lifted its holdings in Amgen by 4.4% in the third quarter. Citizens Financial Group Inc. RI now owns 14,844 shares of the medical research company's stock worth $4,783,000 after purchasing an additional 626 shares during the period. LPL Financial LLC grew its position in Amgen by 0.7% in the 3rd quarter. LPL Financial LLC now owns 751,945 shares of the medical research company's stock valued at $242,284,000 after buying an additional 4,999 shares in the last quarter. Finally, Thompson Siegel & Walmsley LLC increased its stake in Amgen by 7.4% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 41,548 shares of the medical research company's stock valued at $13,387,000 after buying an additional 2,871 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on AMGN. StockNews.com lowered shares of Amgen from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 18th. Leerink Partners cut their price objective on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Royal Bank of Canada reiterated an "outperform" rating and issued a $324.00 price target on shares of Amgen in a research report on Friday, January 24th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Finally, Johnson Rice set a $294.00 target price on shares of Amgen in a report on Wednesday, March 5th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $314.04.
Get Our Latest Stock Report on AMGN
Amgen Stock Performance
Shares of AMGN stock traded down $1.15 during trading on Wednesday, reaching $305.71. The company had a trading volume of 2,374,942 shares, compared to its average volume of 2,545,652. The firm's 50 day simple moving average is $298.92 and its two-hundred day simple moving average is $298.41. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The company has a market capitalization of $164.23 billion, a PE ratio of 40.49, a PEG ratio of 2.63 and a beta of 0.53.
Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.
Amgen Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.11%. Amgen's payout ratio is 126.09%.
Insider Buying and Selling at Amgen
In other news, EVP David M. Reese sold 25,225 shares of the business's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the transaction, the executive vice president now owns 36,922 shares in the company, valued at approximately $11,240,533.68. The trade was a 40.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Murdo Gordon sold 8,771 shares of the business's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total value of $2,585,603.09. Following the transaction, the executive vice president now owns 44,186 shares in the company, valued at $13,025,590.94. This represents a 16.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock valued at $20,644,335 in the last 90 days. 0.69% of the stock is currently owned by insiders.
Amgen Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
